Outlook Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
111 Wood Ave S Unit 100, Iselin, New Jer...Phone Number
(609) 619-3990Website
www.outlooktherapeutics.comRevenue
<$5 MillionStock Symbol
OTLKIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic therapies for retinal diseases. The company specializes in advancing treatments designed to preserve vision and improve outcomes for patients with conditions such as wet age-related macular degeneration and other serious retinal disorders. Through its expertise in biologics, clinical development, and ophthalmology, Outlook Therapeutics aims to deliver high-quality, clinically validated therapies that address unmet needs in retinal care while enhancing accessibility, treatment consistency, and long-term eye health for patients worldwide.Explore more
Outlook Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Outlook Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Outlook Therapeutics has new funding data
Outlook Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Outlook Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Outlook Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Outlook Therapeutics is spiking on competitors!
Product Launch: Get notified when Outlook Therapeutics launches new products
Earning: See what the market has to say on Outlook Therapeutics recently announced quarterly report
Check if Outlook Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Outlook Therapeutics
Compare insights from companies similar to Outlook Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Outlook Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Outlook Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Outlook Therapeutics.
Outlook Therapeutics financials insights
Gather financial insights about Outlook Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$31M
Corporate Investment
$44M
2016
Stock Offering
$29.8M
2018
Share Placement
$15M
2019
Share Placement
$20M
Stock Offering
$26.2M
2020
Share Placement
$10.2M
2021
Stock Offering
$35M
2022
Debt
$31.8M
Outlook Therapeutics Tech Stack
A closer look at the technologies used by Outlook Therapeutics
See more technologies
Most Recent Scoops
Lateral Move
Executive Move
Executive Moves, Lateral Move
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move
New Hire
Executive Move
Executive Moves, New Hire
Hiring Plans
Hiring Plans
Outlook Therapeutics News & Media
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries Deep expertise spans commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructureOutlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
Video webcast now available hereOutlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call August 14, 2026 8:30 AM EDTCompany ParticipantsRobert Jahr - President, CEO & DirectorLawrence...Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
The only FDA-approved ophthalmic bevacizumab, LYTENAVATM, addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Outlook Therapeutics
Sign Up For FreeTo access detailed company insights
Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic therapies for retinal diseases. The company specializes in advancing treatments designed to preserve vision and improve outcomes for patients with conditions such as wet age-related macular degeneration and other serious retinal disor... Read More
